Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT04120753

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04120753
Other papers using this trial's data
  • Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial Journal of cardiovascular pharmacology and therapeutics, 2023 DOI, PubMed 37814541

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04120753. Randomized; no masking; primary purpose treatment. Start 2019-08-26 (actual); primary completion 2021-07-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
Condition
Hypertension
Condition
Dyslipidemias
Intervention (Drug)
OLOMAX 20/5/5mg
Intervention (Drug)
OLOMAX 20/5/10mg
Intervention (Drug)
Olmesartan 20 mg/Amlodipine 5 mg
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct04120753
Content hash
8667956ccfd4c235cb6095c9f26dd3a240f4e5a9673599d4d37a05a1a55f6deb